

**MISSISSIPPI DIVISION OF MEDICAID
DRUG UTILIZATION REVIEW (DUR) BOARD
MINUTES OF THE May 15, 2014 MEETING**

DUR Board Members:	Present	Absent
Allison Bell, Pharm.D.	✓	
James R. "Beau" Cox, Pharm.D.		✓
Logan Davis, Pharm.D.		✓
Lee Greer, M.D.		✓
Antoinette M. Hubble, M.D.	✓	
Sarah Ishee, Pharm.D.		✓
Cherise McIntosh, Pharm.D.	✓	
Jason Parham, M.D.	✓	
Bobby Pactor, M.D.		✓
Sue Simmons, M.D.	✓	
Dennis Smith, R.Ph. (Chair)	✓	
Cynthia Undesser, M.D.	✓	
Total	7	5

Also Present:

DOM Staff:

Judith Clark, R.Ph., DOM Pharmacy Bureau Director; Shannon Hardwick, R.Ph., DOM Clinical Pharmacist, DUR Coordinator; Terri Kirby, R.Ph., DOM Clinical Pharmacist, Stefanie Bryant, DOM Program Integrity

MS-DUR Staff:

Kyle Null, Pharm.D., Ph.D., Clinical Director; Ben Banahan, Ph.D., Project Direct

Xerox Staff:

Leslie Leon, Pharm.D.

Visitors:

Emily Draper, UM pharmacy student; Rachel Strait, UM pharmacy student; Dan Barbera, Lilly; Roger Grotzinger, BMS; Juan Trippe, Reckitt Benckiser; Ken Skidmore, Alexion; Michael Cuccia, Daiichi Sankyo; Tim Melancon, Baxter

Call to Order: Mr. Dennis Smith, Chairman of the Board, called the meeting to order at 1:59 pm. Mr. Smith asked for a motion to accept the minutes from the meeting of February 13, 2014. Dr. Hubble made a motion to accept the minutes with a second from Dr. Undesser. All voted in favor of the motion.

Resource Utilization Review:

Dr. Null reviewed the resource report and noted that there were no specific utilization changes that need attention. Seasonal allergy increasing as expected. Some new expensive products are in top mover due to fact they were not used in prior quarter. Synagis summary shows most patients have shifted to MSCAN. No unexpected findings. MS-DUR will continue to monitor.

Pharmacy Program Update:

Ms. Hardwick reviewed several changes effective July 1, 2014: (1) 340 B pharmacies and providers will have new billing forms; (2) pharmacy reimbursement methodology will change to national average drug acquisition cost (NADAC) and new dispensing fee of \$11.20; and (3) new PDL changes. Plan to roll out a uniform PDL for Medicaid FFS and the MSCAN programs on 10/1/2014. Ms. Clark provided details to Board on 340B and new reimbursement methodology.

Dr. Null noted some of the significant changes in the CMS DUR Annual Report, including pharmacy lock-in policies regarding narcotic use, morphine equivalent dose, buprenorphine guidelines, psychotropic drug use in children and foster children.

New Business:*Identifying Potentially Inappropriate Use of Emergency Overrides*

Dr. Null reviewed patterns of pharmacies using emergency overrides and outliers. Number of fills will probably be changed to rate per prescriptions filled. Ms. Clark explained policy and purpose of the emergency override. Intervention will be for DOM staff to contact the outlier pharmacies and discuss intent of policy and their potential overuse. Pharmacists pointed out the override switch might be retained when refilling. Dr. Hubble suggested sending letters to top 50 as educational. Dr. Hubble made motion for recommendations made by MS-DUR. Seconded by Dr. McIntosh and passed unanimously.

Quantity Limits on Inhaled and Intranasal Products

Dr. Null reviewed an analysis of daily doses prescribed for inhaled and intranasal products provided by DOM and XEROX. No specific recommendations were sought from the DUR Board.

Specialty Drugs – Definition and Management

Dr. Banahan reviewed specialty drug background and the new treatments for Hepatitis C, including a discussion of management techniques for drugs such as Solvaldi. Board suggestions were to possibly include a screening for qualification including past compliance on other medications, alcohol free for 6 months, possibly drug free for 6 months. Dr. Parham expressed a preference for option of hiring additional clinical personnel in DOM to do patient care management since this will grow in importance in the future. Dr. McIntosh made motion to accept recommendations. Seconded by Dr. Hubble. Approved unanimously.

Exceptions Monitoring

Dr. Null noted that all recommended exceptions are from FDA notices and all but first one are safety related issues. Dr. McIntosh made motion to accept recommendations. Seconded by Dr. Hubble. Approved unanimously.

Other Business

Ms. Clark announced that all Board members with expiring terms are willing to serve another term and have been recommended to the Governor. This was preferred since DOM is dealing with universal PDL and other issues that will need to be addressed before new members could become fully oriented.

Next Meeting Information:

Mr. Smith announced next meeting date is August 21, 2014 at 2:00p.m. and thanked everyone for making the effort to attend the DUR Board meeting in order to have a quorum. The meeting adjourned at 3:15 pm.

Submitted,
Evidence-Based DUR Initiative, MS-DUR